Silicone Hydrogel Contact Lenses with Controlled and Extended Release of Latanopr

具有可控和缓释 Latanopr 的硅水凝胶隐形眼镜

• 批准号: 8638312
• 负责人: Mark E. Byrne
• 金额: $ 15.2万
• 依托单位: AUBURN UNIVERSITY AT AUBURN
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-03-01 至 2015-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8638312
• 关键词: Adverse effects; Biological Availability; Blindness; Canis familiaris; Chemistry; Contact Lenses; Diffusion; Dose-Rate; Engineering; Extended-Wear Contact Lenses; Eye; Eyedrops; Glaucoma; Hydrogels; Hydrophilic Contact Lenses; In Vitro; Latanoprost; Lead; Liquid substance; Measures; Mechanics; Memory; Methods; Microfluidics; Modality; Modeling; Optics; Outcome; Oxygen; Patients; Pharmaceutical Preparations; Physiologic Intraocular Pressure; Physiological; Polymers; Problem Solving; Property; Silicones; Solutions; Structure; Swelling; Testing; Therapeutic; Time; Topical application; Water; Weight; Work; compliance behavior; design; effective therapy; in vivo; lacrimal; lens; novel; polymerization; public health relevance

DESCRIPTION: The objective of this project is to develop a novel extended wear contact lens with controllable and sustained release of latanoprost for the duration of wear to treat glaucoma. Glaucoma is the second leading cause of blindness in the world with the total number of cases estimated at over 70 million worldwide. There is a substantial need for more efficacious and convenient delivery of ocular therapeutics, especially glaucoma medication, via non-invasive platforms. Current treatment options predominantly consist of topical eye drops, which lead to significant peaks and valleys in drug concentration and intraocular pressure (IOP). The proposed work aims to solve these problems as well as poor patient compliance with increased latanoprost bioavailability and decreased side effects leading to significantly better patient outcomes. Novel, silicone hydrogel lenses will be rationally designed and synthesized with significant control over latanoprost release and loading while maintaining conventional lens properties such as optical clarity, mechanical properties, and oxygen diffusivity. The structure of the lens will be engineered by varying composition and polymerization conditions to produce macromolecular memory for latanoprost via non-covalent interactions within the polymer lens, leading to strict control of delivery rate and loading. Polymer lens structural, mechanical, optica properties will be characterized as well as in vitro latanoprost release at physiological flow conditions that match tear flow rate and turnover in the eye. In vivo latanoprost release from engineered contact lenses will be evaluated and compared to topical administration in canines measuring IOP and ocular concentration versus time. It is expected that engineered lenses will lead to a constant rate of latanoprost release and lead to approximately constant concentrations of drug in the eye, with little to no peaks and valleys, and a constant decreased IOP for the duration of lens wear.

描述：该项目的目标是开发一种新型的长配戴隐形眼镜，在配戴期间可控制和持续释放拉坦前列素，以治疗青光眼。青光眼是世界上第二大致盲眼病，全球病例总数估计超过 7000 万。迫切需要通过非侵入性平台更有效、更方便地提供眼科治疗药物，尤其是青光眼药物。目前的治疗选择主要包括局部滴眼液，这会导致药物浓度和眼压（IOP）出现显着的峰值和谷值。拟议的工作旨在解决这些问题以及患者依从性差的问题，提高拉坦前列素的生物利用度并减少副作用，从而显着改善患者的治疗效果。 新型硅水凝胶镜片将经过合理设计和合成，显着控制拉坦前列素的释放和负载，同时保持传统镜片的特性，如光学透明度、机械性能和氧扩散率。的结构 该镜片将通过不同的成分和聚合条件进行设计，通过聚合物镜片内的非共价相互作用产生拉坦前列素的大分子记忆，从而严格控制输送速率和负载。将表征聚合物晶状体的结构、机械、光学特性以及在与眼睛中的泪液流速和更新相匹配的生理流动条件下拉坦前列素的体外释放。将评估工程隐形眼镜体内拉坦前列素的释放情况，并将其与犬类局部给药进行比较，测量眼压和眼内浓度随时间的变化。预计工程镜片将导致拉坦前列素释放速率恒定，并导致眼内药物浓度大致恒定，几乎没有峰和谷，并且在镜片佩戴期间眼压持续降低。